RecruitingNot Applicable

Real World Study of Classic Infectious Disease

China10,000 participantsStarted 2020-05-13

Plain-language summary

This study aimed to collect and analyze clinical specimens of patients with classic infectious diseases in the real world. To investigate the epidemiological distribution of classic infectious diseases (brucellosis, epidemic hemorrhagic fever, kala-azar) and treatment options suitable for China.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. sample culture: Brucella;
✓. Specific antigen or antibody (IgG or IgM) positive. epidemic hemorrhagic fever：
✓. latent infection: rK39 antibody positive
✓. patients with the following evidence of kala-azar diagnosis: 1) bone marrow, spleen puncture sample culture: Leishmania; 2) bone marrow, spleen puncture sample smear: Leishmania; 3) clinical symptoms, history of exposure or epidemiology, and positive screening test (rK39 positive)

Exclusion criteria

✕. Patient history data is incomplete
✕. HIV antibody positive and AIDS patients
✕. Patients who participated in other clinical trials during the same period.
✕. Pregnant, lactating women or women of childbearing age who are ready to conceive.

What they're measuring

Number of patients With Prevalence Rate of specific infectious diseases(brucellosis, epidemic hemorrhagic fever, and kala-azar）

Timeframe: 1 day

Trial details

NCT IDNCT04020536

SponsorHuashan Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-01

Contact for this trial

JingWen Ai, Doctor

+86 13764990804 jingwenai1990@126.com

View on ClinicalTrials.gov More Brucelloses trials